squamous NSCLC
Oncology · 2016–2016
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) in patients who have progressed on or after prior platinum-based… | Mar 2016 | Not recommended | input received Lung Foundation |
| nivolumab Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) in patients who have progressed on or after prior platinum-based… | Nov 2016 | Deferred | input received Medical Oncology Group · Lung Foundation |
Who spoke
Lung Foundation · Medical Oncology Group
What the PBS pays
$85M in government benefit over 2024–25, across 7,937 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| nivolumab | $85.2M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 2 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| pembrolizumabPembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | recommended restricted | 2022-02 |
| nivolumabNivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | recommended restricted | 2020-10 |
| afatinibAfatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | terminated | 2017-05 |
| necitumumabNecitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | not recommended | 2016-09 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.